|
Canada-0-BAILIFFS 公司名錄
|
公司新聞:
- Patient Education Brochure | SUBLOCADE® (buprenorphine extended-release . . .
SUBLOCADE contains a medicine called buprenorphine which is an opioid that can cause serious and life-threatening breathing problems, especially if you take or use certain other medicines or drugs
- Resources Patient Support | SUBLOCADE® (buprenorphine extended . . .
What is the most important information I should know about SUBLOCADE? Because of serious risk of potential harm or death from self-injecting SUBLOCADE into a vein (intravenously), it is only available through a restricted program called the SUBLOCADE REMS Program
- Sublocade Patient Education Sheet-EN - addictiontraining. org
This handout provides information on SUBLOCADE®, an injectable formulation of buprenorphine Please read it and let your provider know if you have any questions
- PATIENT INFORMATION – Sublocade Injectio
Sublocade® Injections WHAT IS SUBLOCADE®? Sublocade is a brand name for a long-acting injectable form of bup enorphine used to treat opioid use disorder Sublocade is given to those who started treatment taking a su
- BUPRENORPHINE (Sublocade) Fact Sheet [G] - thecarlatreport. com
FUN FACT: The subcutaneous implant formulation of buprenorphine (Probuphine) was discontinued Its use was severely limited as it was invasive, expensive, and an option only for patients stable on ≤8 mg day
- See full prescribing information for complete boxed warning.
SUBLOCADE injection is available in dosage strengths of 100 mg 0 5 mL and 300 mg 1 5 mL buprenorphine Each injection is a sterile, clear, colorless to yellow to amber solution provided in a single-dose, prefilled syringe with a 19 gauge 5 8-inch needle
- FOR MODERATE TO SEVERE OPIOID USE DISORDER SUBLOCADE: Product Details . . .
SUBLOCADE contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product followed by a dose adjustment period for a minimum of seven days
- Sublocade REMS - Home
What is the SUBLOCADE ® REMS (Risk Evaluation and Mitigation Strategy)? A REMS is a strategy to manage known or potential risks associated with a drug and is required by the Food and Drug Administration (FDA) to ensure the benefits of the drug outweigh its risks
- Buprenorphine Extended-Release Injection (Sublocade®)
Buprenorphine ER is a monthly injection used to treat moderate to severe OUD The injection is a different form of buprenorphine medicines such as Suboxone® or Subutex® A monthly injection may be more convenient than taking a medicine every day How does buprenorphine ER work?
- Informational Resources | SUBLOCADE® (buprenorphine extended-release) HCP
Download important information about clinical resources for your practice and your SUBLOCADE patients See Safety Info, PI, Boxed Warning
|
|